Genetic Technologies Limited's Comment on Competition and Industry Peers
The Company operates in the medical diagnostics and biotechnology industries, focusing on cancer genomics and personalized medicine. It competes with organizations developing Single Nucleotide Polymorphisms (SNP) based risk tests, including Ancestry.com, 23andMe, Color Genomics, deCODE, Intergenetics, ThermoFisher, Counsyl Inc., Invitae Corporation, MyHeritage, and Gene by Gene. Its primary direct-to-consumer product competitors are AncestryDNA, 23andMe, MyHeritage, Gene by Gene, and Color Genomics. The Company seeks to maintain its competitive position by enhancing scientific credibility, advancing technology, improving communication regarding its cancer risk assessment tests, and expanding its product offerings to other serious diseases. Failure to achieve these objectives or the development of superior technologies by competitors could negatively impact the Company’s business.
August 15, 2024
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE), a preeminent name in the field of genomics-based health tests, has unveiled a groundbreaking advancement with the global launch of its geneType Risk Assessment portfolio. The portfolio will be integrated into the company s wholly owned EasyDNA platform, currently operational in 42 countries. This strategic move is anticipated not only to significantly enhance the company s annual revenues, currently at A$7.5 million but also to solidify its standing as a leading innovator in genomics.The geneType portfolio offers a suite of risk assessment tests designed to provide crucial insights into individual susceptibility to a range of serious diseases. From hered...
July 26, 2024
CHARLOTTE, N.C., July 26, 2024: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, Company, GENE), a global leader in genomics-based testing for health, wellness, and serious diseases, has announced a significant strategic shift aimed at optimizing their operations and boosting sales in their largest market, the United States. GENE, the parent company of geneType, has undertaken an exhaustive operations review and is poised to implement a transformational capital light operations model. This strategy is projected to substantially reduce operating costs while propelling the company to new heights in the US market.The innovative capital light model focuses on minimizing in-house laboratory operations, whic...
Publicly Traded Peers of Genetic Technologies Limited
Sources:
Genetic Technologies Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Genetic Technologies Limited versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
